Bacillus Calmette-Guerin (BCG) immunotherapy for bladder cancer: current understanding and perspectives on engineered BCG vaccine (Q27006765)

Jun Miyazaki

2

1 reference

Akira Joraku

3

1 reference

Hiroyuki Nishiyama

4

1 reference

Hideyuki Akaza

5

1 reference

language of work or name

1 reference

January 2013

1 reference

1 reference

104

1 reference

issue

1

1 reference

page(s)

22-7

1 reference

History of bacillus Calmette-Guerin and bladder cancer: an immunotherapy success story

cites work

1 reference

Bladder cancer: epidemiology, staging and grading, and diagnosis.

21 January 2018

1 reference

EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder, the 2011 update

21 January 2018

1 reference

Bladder carcinoma in situ in 2003: state of the art.

21 January 2018

1 reference

Long-term outcomes of intravesical therapy for non-muscle invasive bladder cancer.

21 January 2018

1 reference

A review of current guidelines and best practice recommendations for the management of nonmuscle invasive bladder cancer by the International Bladder Cancer Group

21 January 2018

1 reference

Bacillus Calmette–Guérin treatment of non‐muscle invasive bladder cancer

21 January 2018

1 reference

Bacillus calmette-guerin versus chemotherapy for the intravesical treatment of patients with carcinoma in situ of the bladder: a meta-analysis of the published results of randomized clinical trials

21 January 2018

1 reference

An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Guérin for non-muscle-invasive bladder cancer

21 January 2018

1 reference

BCG intravesical instillations: recommendations for side-effects management

21 January 2018

1 reference

Complications of intravesical therapy for urothelial cancer of the bladder

21 January 2018

1 reference

Expression of antitumor response. Role of attachment and viability of bacillus Calmette-Guérin to bladder cancer cells

21 January 2018

1 reference

Glycosaminoglycan content of human bladders. a method of analysis using cold-cup biopsies

21 January 2018

1 reference

Fibronectin-mediated Calmette-Guerin bacillus attachment to murine bladder mucosa. Requirement for the expression of an antitumor response

21 January 2018

1 reference

Discriminators of mouse bladder response to intravesical Bacillus Calmette-Guerin (BCG).

21 January 2018

1 reference

Characterization of the internalization of bacillus Calmette-Guerin by human bladder tumor cells

21 January 2018

1 reference

Bacterial modulation of antigen processing and presentation

21 January 2018

1 reference

Interleukin 10 induced augmentation of delayed-type hypersensitivity (DTH) enhances Mycobacterium bovis bacillus Calmette-Guérin (BCG) mediated antitumour activity.

21 January 2018

1 reference

Uroepithelial cells can directly respond to Mycobacterium bovis bacillus Calmette-Guérin through Toll-like receptor signalling

21 January 2018

1 reference

IL-23-dependent IL-17 drives Th1-cell responses following Mycobacterium bovis BCG vaccination

21 January 2018

1 reference

IL-17 production by γδ T cells is important for the antitumor effect of Mycobacterium bovis bacillus Calmette-Guérin treatment against bladder cancer

21 January 2018

1 reference

Mycobacterium bovis Bacillus Calmette‐Guérin‐Induced Macrophage Cytotoxicity against Bladder Cancer Cells

21 January 2018

1 reference

Bacillus Calmette-Guérin-pulsed dendritic cells stimulate natural killer T cells and gammadeltaT cells

21 January 2018

1 reference

Prognostic factors in patients with non-muscle-invasive bladder cancer treated with bacillus Calmette-Guérin: multivariate analysis of data from four randomized CUETO trials.

21 January 2018

1 reference

Markers predicting response to bacillus Calmette-Guérin immunotherapy in high-risk bladder cancer patients: a systematic review

21 January 2018

1 reference

Association of polymorphisms in oxidative stress genes with clinical outcomes for bladder cancer treated with Bacillus Calmette-Guérin

21 January 2018

1 reference

Th1 cytokine-secreting recombinant Mycobacterium bovis bacillus Calmette-Guérin and prospective use in immunotherapy of bladder cancer.

21 January 2018

1 reference

Trehalose 6,6'-dimycolate (cord factor) of Mycobacterium tuberculosis induces foreign-body- and hypersensitivity-type granulomas in mice

21 January 2018

1 reference

Roles of lipoarabinomannan in the pathogenesis of tuberculosis

21 January 2018

1 reference

Octaarginine-modified multifunctional envelope-type nanoparticles for gene delivery

21 January 2018

1 reference

Development of a non-viral multifunctional envelope-type nano device by a novel lipid film hydration method

21 January 2018

1 reference

High density of octaarginine stimulates macropinocytosis leading to efficient intracellular trafficking for gene expression.

21 January 2018

1 reference

A multifunctional envelope-type nano device for novel gene delivery of siRNA plasmids.

21 January 2018

1 reference

Immunoprotection against murine bladder carcinoma by octaarginine-modified liposomes incorporating cell wall of Mycobacterium bovis bacillus Calmette-Guérin

21 January 2018

1 reference

The liposome-incorporating cell wall skeleton of Mycobacterium bovis bacillus Calmette-Guéin can directly enhance the susceptibility of cancer cells to lymphokine-activated killer cells through up-regulation of natural-killer group 2, member D ligan

21 January 2018

1 reference

Surface antigen expression on bladder tumor cells induced by bacillus Calmette-Guérin (BCG): A role of BCG internalization into tumor cells

21 January 2018

1 reference

12 December 2020

Requirement of a thymus dependent immune response for BCG-mediated antitumor activity

1 reference

12 December 2020

Intravesical Evans strain BCG therapy: quantitative immunohistochemical analysis of the immune response within the bladder wall

1 reference

12 December 2020

Murine bladder carcinoma cells present antigen to BCG-specific CD4+ T-cells

1 reference

12 December 2020

The therapeutic effects of R8-liposome-BCG-CWS on BBN-induced rat urinary bladder carcinoma.

1 reference

12 December 2020

Spectrum of bacille Calmette-Guérin (BCG) infection after intravesical BCG immunotherapy

1 reference

12 December 2020

Urinary interleukin-2 monitoring during prolonged bacillus Calmette-Guerin treatment: can it predict the optimal number of instillations?

1 reference

12 December 2020

Radio-immunoassay detection of interferon-gamma in urine after intravesical Evans BCG therapy

1 reference

12 December 2020

Urinary IL‐2 assay for monitoring intravesical bacillus Calmette‐Guérin response of superficial bladder cancer during induction course and maintenance therapy

1 reference

12 December 2020

Maintenance therapy with bacillus Calmette-Guérin Connaught strain clearly prolongs recurrence-free survival following transurethral resection of bladder tumour for non-muscle-invasive bladder cancer

1 reference

12 December 2020

Bacillus Calmette-Guérin treatment of existing papillary bladder cancer and carcinoma in situ of the bladder. Four-year results. The Bladder Cancer BCG Study Group

1 reference

12 December 2020

In vivo induction of apoptosis in the thymus by administration of mycobacterial cord factor (trehalose 6,6'-dimycolate)

1 reference

12 December 2020

Urinary interleukin-8 predicts the response of standard and low dose intravesical bacillus Calmette-Guerin (modified Danish 1331 strain) for superficial bladder cancer

1 reference

12 December 2020

Leukocyturia as a predictor of tolerance and efficacy of intravesical BCG maintenance therapy for superficial bladder cancer

1 reference

12 December 2020

Physicochemical cell surface and adhesive properties of coryneform bacteria related to the presence and chain length of mycolic acids.

1 reference

12 December 2020

Urinary Interleukin-8 and 18 predict the response of superficial bladder cancer to intravesical therapy with bacillus Calmette-Guerin

1 reference

12 December 2020

A Clinical Study of PMCJ-9 (Bacillus Calmette-Guerin Connaught Strain) Treatment of Superficial Bladder Cancer and Carcinoma In Situ of the Bladder

1 reference

12 December 2020

Role of interleukin-8 in onset of the immune response in intravesical BCG therapy for superficial bladder cancer

1 reference

12 December 2020

The fate of bacillus Calmette-Guerin after intravesical instillation

1 reference

12 December 2020

Induction of urinary interleukin-1 (IL-1), IL-2, IL-6, and tumour necrosis factor during intravesical immunotherapy with bacillus Calmette-Guérin in superficial bladder cancer

1 reference

12 December 2020

BCG-induced interleukin-6 upregulation and BCG internalization in well and poorly differentiated human bladder cancer cell lines.

1 reference

12 December 2020

Urinary interleukin-2 may predict clinical outcome of intravesical bacillus Calmette-Gu�rin immunotherapy for carcinoma in situ of the bladder

1 reference

12 December 2020

Prognostic value of a T helper 1 urinary cytokine response after intravesical bacillus Calmette-Guerin treatment for superficial bladder cancer

1 reference

12 December 2020

Bladder cancer clinical guidelines panel summary report on the management of nonmuscle invasive bladder cancer (stages Ta, T1 and TIS). The American Urological Association

1 reference

12 December 2020

Intracavitary Bacillus Calmette-Guerin in the treatment of superficial bladder tumors

1 reference

12 December 2020

Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study

1 reference

12 December 2020

NK cells are essential for effective BCG immunotherapy

1 reference

12 December 2020